drugset
drugset / Trial / NCT07056517

Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults

NCT07056517 ↗

Phase 1 Completed 21 enrolled Aclipse Two Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of lobeglitazone administered as M107 Orally Disintegrating Tablet and Duvie tablet in healthy adult participants under fasted and fed conditions.

Timeline

Start
2025-07-11
Primary completion
2025-09-22
Completion
2025-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobeglitazone Small molecule 0.4 mg Oral
Subject Lobeglitazone Small molecule 0.415 mg Oral
Subject Lobeglitazone Small molecule 0.8 mg Oral
Subject Lobeglitazone Small molecule 1.2 mg Oral

Indications

No indication recorded.